Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting
Trevena, Inc. (TRVN)
Last trevena, inc. earnings: 3/12 07:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.trevena.com/investor-relations
Company Research
Source: GlobeNewswire
Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), in Orlando, FL. The poster presentation featured results from a Phase 1 first-in-human study that evaluated the safety, tolerability, and pharmacokinetics (PK) of TRV250, the Company’s novel G protein-selective delta-receptor agonist being developed for the acute treatment of migraine. TRV250 was well-tolerated up to 30 mg, with a PK profile appropriate for an acute migraine therapy. There were no serious adverse events and no clinically significant changes in EEG, ECG, or other safety parameters. “We are excited to be pu
Show less
Read more
Impact Snapshot
Event Time:
TRVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVN alerts
High impacting Trevena, Inc. news events
Weekly update
A roundup of the hottest topics
TRVN
News
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena Reports Third Quarter 2024 Results and Provides Business UpdateGlobeNewswire
TRVN
Analyst Actions
- 11/14/24 - HC Wainwright
TRVN
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- TRVN's page on the SEC website